In clinical practice, patients with isocitrate dehydrogenase (NADP(+)) 1 (IDH1)R132H mutation, a diagnostic marker and prognostic indicator of GBM, gain survival benefit in contrast to those without the mutation in both primary and secondary GBM [6, 7]. Here, IDH1 is linked to glioblastoma.